Peter E. Boyd, Chief People Officer of Aquestive Therapeutics, Inc. (NASDAQ:AQST), filed a Form 4 on September 11, 2026 reporting a warrant exercise transaction dated September 9, 2026.

Key Highlights

  • Transaction type: Boyd exercised a Common Stock Purchase Warrant (transaction code X) for 2,293 shares of common stock on September 9, 2026.
  • Exercise price: The warrant carried an exercise price of $0.96 per share, paid in cash according to the filing.
  • Warrant origin: The warrant was issued on June 8, 2022, pursuant to a Securities Purchase Agreement dated June 6, 2022, and became exercisable on December 8, 2022.
  • Warrant expiration: The warrant was set to expire on June 8, 2027, per the filing's explanation of responses.
  • Post-transaction ownership: Following the exercise, Boyd directly beneficially owned 284,024 shares of common stock; the warrant position was reduced to 0 derivative securities.

Boyd's Warrant Exercise Reduces Derivative Position to Zero at Aquestive Therapeutics

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Peter E. Boyd, identified as Chief People Officer of Aquestive Therapeutics, Inc., reported the exercise of a Common Stock Purchase Warrant on September 9, 2026. The filing discloses that the exercise was for cash, with 2,293 shares of common stock acquired at an exercise price of $0.96 per share.

The filing's explanation of responses states that the warrant was originally issued to Boyd on June 8, 2022, under a Securities Purchase Agreement dated June 6, 2022. The warrant became exercisable on December 8, 2022, and carried an expiration date of June 8, 2027. The transaction code reported is "X," consistent with the exercise of a derivative security. Following the transaction, the filing reports that Boyd's direct beneficial ownership of common stock stands at 284,024 shares, while the number of derivative securities beneficially owned following the transaction is reported as 0.

The Form 4 was signed by Thomas Zalewski as Attorney-In-Fact on September 11, 2026. The filing was made by one reporting person and covers non-derivative securities in Table I and derivative securities in Table II, with the warrant line in Table II showing a disposition of 2,293 units and a resulting balance of zero.

What Was Disclosed

Peter E. Boyd, Chief People Officer of Aquestive Therapeutics, Inc. (NASDAQ:AQST), disclosed the cash exercise of a 2,293-share common stock warrant at $0.96 per share on September 9, 2026, leaving him with 284,024 shares of common stock and no remaining warrant position.